Unknown NA INTERVENTIONAL 1-arm NCT04867330

Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC

Induction Chemotherapy of Toripalimab With Docetaxel and Cisplatin Followed by De-escalation of Chemoradiotherapy Density in HPV-related Oropharyngeal Carcinoma in Chinese Populations

Sponsor: Fudan University

Conditions De-escalation Immune Checkpoint Inhibitor Oropharyngeal Carcinoma

Interventions Toxicities reduced treatment arm

Updated 4 times since 2021 Last updated: Apr 27, 2021 Started: Feb 1, 2021 Primary completion: May 31, 2021 Completion: Jan 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on De-escalation and Immune Checkpoint Inhibitor, this trial is ongoing. The trial is conducted by Fudan University and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Unknown NA

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
May 2021 — Jul 2024 [monthly]

Recruiting NA

First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China